NCT05024721

Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis

A Multicenter, Randomized, Double-blind, Active-controlled, Phase Ⅲ Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 326 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 19 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the safety and clinical efficacy of HIP2101 in patients with acute or chronic gastritis.

Conditions

• Gastritis

Interventions

Type	Name	Description
DRUG	HIP2101	Test drug
DRUG	RLD2101	Reference drug
DRUG	HPP2101	Placebo drug
DRUG	HPP2102	Placebo drug

Timeline

• Start date: 2021-08-09
• Primary completion: 2022-03-07
• Completion: 2022-03-07
• First posted: 2021-08-27
• Last updated: 2022-07-14

Locations

1 site across 1 country: South Korea